Trial Profile
ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Bicalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ATLAS
- Sponsors Aragon Pharmaceuticals; Janssen-Cilag
- 02 Jan 2024 Planned End Date changed from 1 Dec 2028 to 29 Dec 2028.
- 02 Jan 2024 Planned primary completion date changed from 1 Jun 2024 to 28 Jun 2024.
- 05 Dec 2023 Planned End Date changed from 6 Oct 2026 to 1 Dec 2028.